Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001564590-21-016996
Filing Date
2021-03-31
Accepted
2021-03-31 14:14:04
Documents
11
Period of Report
2020-12-31

Document Format Files

Seq Description Document Type Size
1 10-K ikt-10k_20201231.htm 10-K 2608022
2 EX-4.19 ikt-ex419_337.htm EX-4.19 37054
3 EX-21.1 ikt-ex211_338.htm EX-21.1 1196
4 EX-31.1 ikt-ex311_336.htm EX-31.1 10864
5 EX-31.2 ikt-ex312_335.htm EX-31.2 10882
6 EX-32.1 ikt-ex321_334.htm EX-32.1 7714
7 EX-32.2 ikt-ex322_333.htm EX-32.2 7635
8 GRAPHIC gkn4pooo3dxi000001.jpg GRAPHIC 316345
9 GRAPHIC gkn4pooo3dxi000002.jpg GRAPHIC 159464
10 GRAPHIC gkn4pooo3dxi000003.jpg GRAPHIC 297676
11 GRAPHIC gkn4pooo3dxi000004.jpg GRAPHIC 90566
  Complete submission text file 0001564590-21-016996.txt   3874810
Mailing Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339
Business Address 3350 RIVERWOOD PARKWAY SE, SUITE 1900 ATLANTA GA 30339 678-392-3419
Inhibikase Therapeutics, Inc. (Filer) CIK: 0001750149 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39676 | Film No.: 21792422
SIC: 2836 Biological Products, (No Diagnostic Substances)